Article Sidebar

PDF (Tiếng Việt)
Published: 2022-10-06
Abstract Views: 161
Views PDF (Tiếng Việt): 138
DOI: https://doi.org/10.52852/tcncyh.v157i9.977
Issue
Vol. 157 No. 9 (2022)
Section
Các bài báo
How to Cite
Thúy, Đào T. D. ., Anh, V. M. ., Thúy, Đinh T. T. ., Trang, N. T. ., & Giang, L. M. . (2022). 23. Factors associated with treatment discontinuation among people receiving buprenorphine in three mountanous provinces in North Vietnam. Journal of Medical Research, 157(9), 192-201. https://doi.org/10.52852/tcncyh.v157i9.977

23. Factors associated with treatment discontinuation among people receiving buprenorphine in three mountanous provinces in North Vietnam

Dao Thi Dieu Thuy, Vu Minh Anh, Dinh Thi Thanh Thuy, Nguyen Thu Trang, Le Minh Giang

Main Article Content

Abstract

This is a cohort study performed to explore associated factors with opioid treatment discontinuation among people receiving buprenorphine. 130 patients receiving buprenorphine in 3 mountainous provinces in north Vietnamparticipated in the study. Inclusion criteria included: 16 years old or older, buprenorphine initiated between Sep 2019 and Dec 2019, and volunteered to participate the study. Data sources included extracting monthly data from medical records and face-to-face interviews at two time points, Jun 2020 and Sep 2020. Our findings showed the discontinuation rates at the 6 months, 9 months, and 12-months after starting buprenorphine were 11.5%, 21.5% and 26.2%, respectively. Older age, (aOR = 0.9, 95%CI: 0.87 - 0.97), participating in counselling sessions at clinics (aOR = 0.25, 95%CI: 0.12 - 0.52) decreased the hazards of discontinuation in buprenorphine. Being female increased the hazard of discontinuation compared to male (aOR = 4.2, 95%CI: 1.06 - 16.69). Our study highlighted the importance of counselling sessions in retaining patients on buprenorphine. More studies are needed to address risk factors of treatment discontinuation and improve the retention of patients receiving buprenorphine treatment.

Article Details

Keywords

opioid treatment, buprenorphine, dropout, discontinuation

References

1. Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry. 2001;58(8):729-736.
2. Korthuis PT, Josephs JS, Fleishman JA, et al. Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions. J Subst Abuse Treat. 2008;35(3):294-303.
3. Deering DEA, Sheridan J, Sellman JD, et al. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav. 2011;36(6):636-642.
4. Lin C, Wu Z, Detels R. Opiate users' perceived barriers against attending methadone maintenance therapy: A qualitative study in China. Subst Use Misuse. 2011;46(9):1190-1198.
5. Kurz M, Min JE, Dale LM, Nosyk B. Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. J Subst Abuse Treat. 2022;133:108647.
6. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S22-32.
7. Korthuis PT, Fiellin DA, Fu R, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: The role of buprenorphine. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S83-90.
8. Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(01).
9. Button D, Cook R, King C, et al. Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam. Int J Drug Policy. 2021;100:103503.
10. Farnum SO, Makarenko I, Madden L, et al. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction. Published online May 19, 2020.
11. Wyse JJ, McGinnis KA, Edelman EJ, et al. Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV. AIDS Behav. Published online September 8, 2021.
12. Eren K, Schuster J, Herschell A, et al. Association of counseling and psychotherapy on retention in medication for addiction treatment within a large medicaid population. J Addict Med. Published online September 22, 2021.
13. Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768-776.
14. Lopian KM, Chebolu E, Kulak JA, Kahn LS, Blondell RD. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder. Journal of Substance Abuse Treatment. 2019;97:1-6.
15. Zhang P, Tossone K, Ashmead R, et al. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data. Journal of Substance Abuse Treatment. Published online December 2021:108686.